Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank (eurIPFreg)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02951416 |
Recruitment Status :
Recruiting
First Posted : November 1, 2016
Last Update Posted : November 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Born out of the European Union 7th Framework Programme funded project European IPF Network (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of longitudinal data from IPF patients, including control groups of patients with other lung diseases. The registry was initiated with the intention of creating a permanent and continuously growing record of well defined data on IPF in Europe, in order to increase the chances of finding better treatment options for this devastating disease.
Clinical colleagues who would like to actively participate (both in terms of patient recruitment and data analysis) are invited to contact us (http://www.pulmonary-fibrosis.net/).
Condition or disease | Intervention/treatment |
---|---|
Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonia Interstitial Lung Diseases Diffuse Parenchymal Lung Diseases | Other: patient registry (observation and biomaterial sampling) |
The group's work aims to foster research on Idiopathic Pulmonary Fibrosis (IPF), the most aggressive form of an Idiopathic Interstitial Pneumonia (IIP). Within the eurIPFreg we, the eurIPFreg steering committee and a growing number of external site investigators, aim to describe the natural course of IPF and other IIPs, to identify risk factors that are associated with the evolution of the disease and to sample biomaterials that may serve as underlying basis for translational research activities.
IPF and non-specific interstitial pneumonia (NSIP), as well as the other entities of IIPs (cryptogenic organizing pneumonia, COP; desquamative interstitial pneumonia, DIP; respiratory bronchiolitis interstitial lung disease, RB-ILD; lymphoid interstitial pneumonia, LIP; acute interstitial pneumonia, AIP) are frequently progressive, fibroproliferative diseases of unknown etiology, affecting the lung parenchyma. Patients with IPF have the most devastating prognosis within the group of IIPs, with a median survival rate of 2-3 years.
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 2000 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 60 Months |
Official Title: | The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank) |
Study Start Date : | September 2009 |
Estimated Primary Completion Date : | January 2025 |
Estimated Study Completion Date : | January 2040 |

Group/Cohort | Intervention/treatment |
---|---|
Idiopathic Pulmonary Fibrosis (IPF)
IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646). Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Non-specific interstitial pneumonia
Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Cryptogenic organising pneumonia (COP)
COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Acute interstitial pneumonia (AIP)
Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Lymphoid interstitial pneumonia (LIP)
Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)). Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
respiratory bronchiolitis-ILD (RB-ILD)
Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
|
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Desquamative Interstitial Pneumonia
Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Sarcoidosis
Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Lung Cancer
Histological confirmation of Lung Cancer. Patients will be included as control group. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Chronic Obstructive Pulmonary Disease
Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Pulmonary Hypertension
Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Sleep Apnea
Sleep Apnea diagnosed by polysomnography. Patients will be included as control group. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Asthma
Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group. Patient registry (observation and biomaterial sampling). |
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
Control/Health Individuals
Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
|
Other: patient registry (observation and biomaterial sampling)
data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected |
- clinical course of patients with Interstitial Lung Diseases (ILD) [ Time Frame: 5 years ]change of lung function parameter such as forced vital capacity (FVC), diffusing lung capacity (DLCO) over time mortality symptoms (reported in patients questionnaires)
- Comorbidities of patients with ILD [ Time Frame: 5 years ]reported in patients and physicians questionnaires
- Infections in lung function of patients with ILD [ Time Frame: 5 years ]reported in patients and physicians questionnaires
- Quality of life of patients with ILD [ Time Frame: 5 years ]reported in patients and physicians questionnaires, EQ5D (European quality of life 5-dimensions) questionnaire
- Health care utilization of patients with ILD [ Time Frame: 5 years ]reported in patients questionnaires
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Informed consent signed
Exclusion Criteria:
- No informed consent signed

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02951416
Contact: Andreas Guenther, MD | +49 64198542502 | andreas.guenther@innere.med.uni-giessen.de | |
Contact: Jasmin Wagner, MD | +49 64198542502 | jasmin.wagner@innere.med.uni-giessen.de |
Austria | |
Medizinische Universität Wien | Recruiting |
Vienna, Austria | |
Contact: Walter Klepetko | |
France | |
Centre Hospitalier Universitaire Dijon | Recruiting |
Dijon, France | |
Contact: Philippe Bonniaud | |
Hopital Bichat Paris | Recruiting |
Paris, France | |
Contact: Bruno Crestani | |
Germany | |
Andreas Guenther | Recruiting |
Giessen, Germany, 35392 | |
Contact: Andreas Guenther, MD 64198542502 ext 502 andreas.guenther@innere.med.uni-giessen.de | |
Principal Investigator: Andreas Guenther, MD | |
Sub-Investigator: Daniel von der Beck, MD | |
Sub-Investigator: Fotios Drakopanagiotakis, MD | |
Lungenfachklinik Waldhof Elgershausen | Recruiting |
Greifenstein, Germany | |
Contact: Andreas Guenther, MD +49 6449 927 ext 262 | |
Principal Investigator: Andreas Guenther, MD | |
Sub-Investigator: Benjamin Loeh, MD | |
Italy | |
Università degli Studi di Catania | Recruiting |
Catania, Italy | |
Contact: Carlo Vancheri | |
United Kingdom | |
Royal Brompton Hospital | Recruiting |
London, United Kingdom | |
Contact: Atholl Wells |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Andreas Guenther, Professor of Internal Medicine, University of Giessen |
ClinicalTrials.gov Identifier: | NCT02951416 |
Other Study ID Numbers: |
EurIPFreg_150609 |
First Posted: | November 1, 2016 Key Record Dates |
Last Update Posted: | November 20, 2017 |
Last Verified: | November 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Pneumonia Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis |
Lung Diseases, Interstitial Idiopathic Interstitial Pneumonias Respiratory Tract Diseases Respiratory Tract Infections |